An open, vendor-neutral standard for reproducibility, traceability, and human accountability in automated and computer-assisted healthcare coverage decisions.
Coverage decisions — prior authorization, utilization review, claims adjudication, downcoding — are consequential, governed by written policy, and subject to appeal, audit, regulation, and litigation. A growing share of these decisions are now produced or materially assisted by software, including probabilistic artificial intelligence.
Courts have begun compelling disclosure of payer decision algorithms. States have begun requiring annual certification of insurer AI. Federal rules now require a specific reason for every denial. The direction of all of it is a single demand:
A decision system that cannot answer cannot be meaningfully appealed, audited, or defended. RCD-1 defines, in testable requirements, what a system must be able to show when examined.
Reading clinical reality is inherently interpretive. Deciding under written policy is not. RCD-1 requires that systems separate the understanding layer (which reads and structures source material, and may use any technique, including large language models) from the decision layer (which determines outcomes, and must be deterministic, policy-bound, and reproducible).
The standard does not prohibit any technology. It constrains where probabilistic outputs may carry decision authority: nowhere.
| Level | Name | Meaning |
|---|---|---|
| RCD-1 / L1 | Traceable | Decisions are documented, reasoned at the criterion level, policy-versioned, and humanly accountable. |
| RCD-1 / L2 | Reproducible | L1, plus a deterministic decision layer in which probabilistic components carry no decision authority. |
| RCD-1 / L3 | Independently Verified | L2, plus the Re-Run Test executed by an independent party and an annual officer-signed attestation. |
Levels create an adoption path: L1 is achievable by well-run platforms today. L2 and L3 are architectural claims that can be verified, not asserted.
RCD-1 is designed so that conformance produces, as a by-product, the evidence demanded by current and emerging law:
The comment period for Working Draft v0.9 is open through September 2026. The Working Group invites co-conveners and reviewers from provider organizations, payers, professional associations, standards bodies, technology vendors, academic researchers, patient advocates, and regulators.
Version 1.0 will be ratified by the assembled Working Group. No single organization — including the convener — holds veto over its content. The standard is and will remain free to implement: no licensing fee, no certification monopoly, no membership requirement.